BACKGROUND: Curative-intent treatment for localized hilar cholangiocarcinoma (HC) requires surgical resection. However, the effect of adjuvant therapy (AT) on survival is unclear. We analyzed the impact of AT on overall (OS) and recurrence free survival (RFS) in patients undergoing curative resection. METHODS: We reviewed patients with resected HC between 2000 and 2015 from the ten institutions participating in the U.S. Extrahepatic Biliary Malignancy Consortium. We analyzed the impact of AT on RFS and OS. The probability of RFS and OS were calculated in the method of Kaplan and Meier and analyzed using multivariate Cox regression analysis. RESULTS: A total of 249 patients underwent curative resection for HC. Patients who received AT and those who did not had similar demographic and preoperative features. In a multivariate Cox regression analysis, AT conferred a significant protective effect on OS (HR 0.58, P = 0.013), and this was maintained in a propensity matched analysis (HR 0.66, P = 0.033). The protective effect of AT remained significant when node negative patients were excluded (HR 0.28, P = 0.001), while it disappeared (HR 0.76, P = 0.260) when node positive patients were excluded. CONCLUSIONS: AT should be strongly considered after curative-intent resection for HC, particularly in patients with node positive disease.
BACKGROUND: Curative-intent treatment for localized hilar cholangiocarcinoma (HC) requires surgical resection. However, the effect of adjuvant therapy (AT) on survival is unclear. We analyzed the impact of AT on overall (OS) and recurrence free survival (RFS) in patients undergoing curative resection. METHODS: We reviewed patients with resected HC between 2000 and 2015 from the ten institutions participating in the U.S. Extrahepatic Biliary Malignancy Consortium. We analyzed the impact of AT on RFS and OS. The probability of RFS and OS were calculated in the method of Kaplan and Meier and analyzed using multivariate Cox regression analysis. RESULTS: A total of 249 patients underwent curative resection for HC. Patients who received AT and those who did not had similar demographic and preoperative features. In a multivariate Cox regression analysis, AT conferred a significant protective effect on OS (HR 0.58, P = 0.013), and this was maintained in a propensity matched analysis (HR 0.66, P = 0.033). The protective effect of AT remained significant when node negative patients were excluded (HR 0.28, P = 0.001), while it disappeared (HR 0.76, P = 0.260) when node positive patients were excluded. CONCLUSIONS: AT should be strongly considered after curative-intent resection for HC, particularly in patients with node positive disease.
Authors: John C Mansour; Thomas A Aloia; Christopher H Crane; Julie K Heimbach; Masato Nagino; Jean-Nicolas Vauthey Journal: HPB (Oxford) Date: 2015-08 Impact factor: 3.647
Authors: Eric Tran; Simon Turcotte; Alena Gros; Paul F Robbins; Yong-Chen Lu; Mark E Dudley; John R Wunderlich; Robert P Somerville; Katherine Hogan; Christian S Hinrichs; Maria R Parkhurst; James C Yang; Steven A Rosenberg Journal: Science Date: 2014-05-09 Impact factor: 47.728
Authors: A Nakeeb; H A Pitt; T A Sohn; J Coleman; R A Abrams; S Piantadosi; R H Hruban; K D Lillemoe; C J Yeo; J L Cameron Journal: Ann Surg Date: 1996-10 Impact factor: 12.969
Authors: Kenichi Matsuo; Flavio G Rocha; Kaori Ito; Michael I D'Angelica; Peter J Allen; Yuman Fong; Ronald P Dematteo; Mithat Gonen; Itaru Endo; William R Jarnagin Journal: J Am Coll Surg Date: 2012-06-28 Impact factor: 6.113
Authors: D P S Sohal; K Mykulowycz; T Uehara; U R Teitelbaum; N Damjanov; B J Giantonio; M Carberry; P Wissel; M Jacobs-Small; P J O'Dwyer; A Sepulveda; W Sun Journal: Ann Oncol Date: 2013-10-20 Impact factor: 32.976
Authors: Markus W Löffler; P Anoop Chandran; Karoline Laske; Christopher Schroeder; Irina Bonzheim; Mathias Walzer; Franz J Hilke; Nico Trautwein; Daniel J Kowalewski; Heiko Schuster; Marc Günder; Viviana A Carcamo Yañez; Christopher Mohr; Marc Sturm; Huu-Phuc Nguyen; Olaf Riess; Peter Bauer; Sven Nahnsen; Silvio Nadalin; Derek Zieker; Jörg Glatzle; Karolin Thiel; Nicole Schneiderhan-Marra; Stephan Clasen; Hans Bösmüller; Falko Fend; Oliver Kohlbacher; Cécile Gouttefangeas; Stefan Stevanović; Alfred Königsrainer; Hans-Georg Rammensee Journal: J Hepatol Date: 2016-07-07 Impact factor: 25.083
Authors: Junya Toyoda; Kota Sahara; Shishir K Maithel; Daniel E Abbott; George A Poultsides; Christopher Wolfgang; Ryan C Fields; Jin He; Charles Scoggins; Kamran Idrees; Perry Shen; Itaru Endo; Timothy M Pawlik Journal: Ann Surg Oncol Date: 2022-06-29 Impact factor: 4.339
Authors: Umberto Cillo; Constantino Fondevila; Matteo Donadon; Enrico Gringeri; Federico Mocchegiani; Hans J Schlitt; Jan N M Ijzermans; Marco Vivarelli; Krzysztof Zieniewicz; Steven W M Olde Damink; Bas Groot Koerkamp Journal: Liver Int Date: 2019-05 Impact factor: 5.828
Authors: Jian Zhao; Wei Zhang; Jun Zhang; Yi Zhang; Wen-Jie Ma; Si-Yun Liu; Fu-Yu Li; Bin Song Journal: BMC Cancer Date: 2020-09-03 Impact factor: 4.430